Cargando…

Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma

Anti-CD133 monoclonal antibody (Ab)-conjugated poly(lactide-co-glycolide) (PLGA) nanocarriers, for the targeted delivery of oxaliplatin (OXA) and superparamagnetic nanoparticles (IO-OA) to colorectal cancer cells (CaCo-2), were designed, synthesized, characterized, and evaluated in this study. The c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zumaya, Alma Lucia Villela, Rimpelová, Silvie, Štějdířová, Markéta, Ulbrich, Pavel, Vilčáková, Jarmila, Hassouna, Fatima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835878/
https://www.ncbi.nlm.nih.gov/pubmed/35163122
http://dx.doi.org/10.3390/ijms23031200
_version_ 1784649540615274496
author Zumaya, Alma Lucia Villela
Rimpelová, Silvie
Štějdířová, Markéta
Ulbrich, Pavel
Vilčáková, Jarmila
Hassouna, Fatima
author_facet Zumaya, Alma Lucia Villela
Rimpelová, Silvie
Štějdířová, Markéta
Ulbrich, Pavel
Vilčáková, Jarmila
Hassouna, Fatima
author_sort Zumaya, Alma Lucia Villela
collection PubMed
description Anti-CD133 monoclonal antibody (Ab)-conjugated poly(lactide-co-glycolide) (PLGA) nanocarriers, for the targeted delivery of oxaliplatin (OXA) and superparamagnetic nanoparticles (IO-OA) to colorectal cancer cells (CaCo-2), were designed, synthesized, characterized, and evaluated in this study. The co-encapsulation of OXA and IO-OA was achieved in two types of polymeric carriers, namely, PLGA and poly(lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) by double emulsion. PLGA_IO-OA_OXA and PEGylated PLGA_IO-OA_OXA nanoparticles displayed a comparable mean diameter of 207 ± 70 nm and 185 ± 119 nm, respectively. The concentration of the released OXA from the PEGylated PLGA_IO-OA_OXA increased very rapidly, reaching ~100% release after only 2 h, while the PLGA_IO-OA_OXA displayed a slower and sustained drug release. Therefore, for a controlled OXA release, non-PEGylated PLGA nanoparticles were more convenient. Interestingly, preservation of the superparamagnetic behavior of the IO-OA, without magnetic hysteresis all along the dissolution process, was observed. The non-PEGylated nanoparticles (PLGA_OXA, PLGA_IO-OA_OXA) were selected for the anti-CD133 Ab conjugation. The affinity of Ab-coated nanoparticles for CD133-positive cells was examined using fluorescence microscopy in CaCo-2 cells, which was followed by a viability assay.
format Online
Article
Text
id pubmed-8835878
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88358782022-02-12 Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma Zumaya, Alma Lucia Villela Rimpelová, Silvie Štějdířová, Markéta Ulbrich, Pavel Vilčáková, Jarmila Hassouna, Fatima Int J Mol Sci Article Anti-CD133 monoclonal antibody (Ab)-conjugated poly(lactide-co-glycolide) (PLGA) nanocarriers, for the targeted delivery of oxaliplatin (OXA) and superparamagnetic nanoparticles (IO-OA) to colorectal cancer cells (CaCo-2), were designed, synthesized, characterized, and evaluated in this study. The co-encapsulation of OXA and IO-OA was achieved in two types of polymeric carriers, namely, PLGA and poly(lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) by double emulsion. PLGA_IO-OA_OXA and PEGylated PLGA_IO-OA_OXA nanoparticles displayed a comparable mean diameter of 207 ± 70 nm and 185 ± 119 nm, respectively. The concentration of the released OXA from the PEGylated PLGA_IO-OA_OXA increased very rapidly, reaching ~100% release after only 2 h, while the PLGA_IO-OA_OXA displayed a slower and sustained drug release. Therefore, for a controlled OXA release, non-PEGylated PLGA nanoparticles were more convenient. Interestingly, preservation of the superparamagnetic behavior of the IO-OA, without magnetic hysteresis all along the dissolution process, was observed. The non-PEGylated nanoparticles (PLGA_OXA, PLGA_IO-OA_OXA) were selected for the anti-CD133 Ab conjugation. The affinity of Ab-coated nanoparticles for CD133-positive cells was examined using fluorescence microscopy in CaCo-2 cells, which was followed by a viability assay. MDPI 2022-01-21 /pmc/articles/PMC8835878/ /pubmed/35163122 http://dx.doi.org/10.3390/ijms23031200 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zumaya, Alma Lucia Villela
Rimpelová, Silvie
Štějdířová, Markéta
Ulbrich, Pavel
Vilčáková, Jarmila
Hassouna, Fatima
Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma
title Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma
title_full Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma
title_fullStr Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma
title_full_unstemmed Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma
title_short Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma
title_sort antibody conjugated plga nanocarriers and superparmagnetic nanoparticles for targeted delivery of oxaliplatin to cells from colorectal carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835878/
https://www.ncbi.nlm.nih.gov/pubmed/35163122
http://dx.doi.org/10.3390/ijms23031200
work_keys_str_mv AT zumayaalmaluciavillela antibodyconjugatedplgananocarriersandsuperparmagneticnanoparticlesfortargeteddeliveryofoxaliplatintocellsfromcolorectalcarcinoma
AT rimpelovasilvie antibodyconjugatedplgananocarriersandsuperparmagneticnanoparticlesfortargeteddeliveryofoxaliplatintocellsfromcolorectalcarcinoma
AT stejdirovamarketa antibodyconjugatedplgananocarriersandsuperparmagneticnanoparticlesfortargeteddeliveryofoxaliplatintocellsfromcolorectalcarcinoma
AT ulbrichpavel antibodyconjugatedplgananocarriersandsuperparmagneticnanoparticlesfortargeteddeliveryofoxaliplatintocellsfromcolorectalcarcinoma
AT vilcakovajarmila antibodyconjugatedplgananocarriersandsuperparmagneticnanoparticlesfortargeteddeliveryofoxaliplatintocellsfromcolorectalcarcinoma
AT hassounafatima antibodyconjugatedplgananocarriersandsuperparmagneticnanoparticlesfortargeteddeliveryofoxaliplatintocellsfromcolorectalcarcinoma